Physitrack Q4 2024: Softer topline but positive FCF - Redeye

Redeye comments on Physitrack’s Q4 figures, which slightly missed our expectations on topline. On the positive side, ARR grew by 2% q/q accompanied by a positive cash flow. Following the report, we expect to make moderate adjustments to our near-term estimates and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/987140/physitrack-q4-2024-softer-topline-but-positive-fcf?utm_source=finwire&utm_medium=RSS